Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New findings from St. James University describe advances in breast cancer
March 20th, 2008
According to a study from Leeds, the United Kingdom, "Tamoxifen remains therapy of choice for premenopausal estrogen receptor a-positive breast cancer. However, resistance and recurrence are serious problems." "Our previous work indicated that carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) was significantly upregulated in tamoxifen-resistant (TAMr) MCF-7 derivatives. The aim of this study was to determine the functional role of CEACAM6 in endocrine-resistant breast cancer and to retrospectively test whether it was predictive of resistance in a large cohort of breast cancers with long-term follow-up. siRNA silencing of CEACAM6 was done in TAMr cells and...
Source: Women's Health Weekly (2008-03-20)
|
